Several classes of HER2-targeted agents have been developed for the treatment of HER2-positive (HER2+) breast cancer, including monoclonal antibodies (Trastuzumab and Pertuzumab), small molecule tyrosine kinase inhibitors (Lapatinib and Neratinib) and antibody-drug conjugates (trastuzumab emtansine T-DM1) [1–4]. Here, ERBB2 is linked to breast cancer.